| Ticker Symbol: | CELG |
|---|---|
| Exchange: | NASD |
| Contact Info: | 86 Morris Avenue Summit NJ 07901 908 673-9000 |
| CEO/President: | Sol J. Barer |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases. |
| Shares Outstanding: | 435,870 (000) | Market Value: | 31,132,260 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 81.89% | Number of Inst.Shareholders: | 2.40% |
| Last Quarter Sales: | 571.46 ($Mil.) | Last Quarter Net Income: | 119.88 ($Mil.) |
| Last Quarter EPS: | 0.31 | P/E Ratio: | 56 |
| Most Recent Earnings: | 0.37 on 07/24/08 | Earnings Per Share: | -3.45 |
| Most Recent Split: | 2-1 on 02/27/06 | Annual Dividend Rate: | 0 |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |


| AMGEN | +36.90 | 63.10 | |
| GILEAD SCIENCES | +27.50 | 51.38 | |
| AMYLIN PHARMA I | -53.60 | 22.27 | |
| BIOGEN IDEC INC | -16.80 | 50.17 | |
| GENENTECH INC | +35.90 | 97.68 |
